大腸癌治療薬の世界市場:治療、研究開発、市場予測...市場調査レポートについてご紹介

【英文タイトル】Colorectal Cancer Drugs Industry and Market: Therapies, R&D and Forecasts 2015-2025

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1. Report Overview
1.1 Overview of the World Market for Colorectal Cancer Drugs
1.2 Why You Should Read This Report
1.3 How This Study Delivers
1.4 Main Questions Answered by this Analysis
1.5 Who is this Report For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain

2. Introduction to Colorectal Cancer and Treatments
2.1 Pathophysiology of Colorectal Cancer
2.2 Epidemiology of Colorectal Cancer
2.2.1 Incidence – Increases with Age
2.2.2 Mortality – Fourth-Leading Cause of Cancer Death
2.2.3 Survival – Depends on Stage of Cancer
2.3 Diagnosis – Benefits and Limitations
2.4 Treatment and Staging
2.4.1 Treatment Options
2.4.2 Staging in Colorectal Cancers
2.4.3 Treatment Depending on Stages

3. The World Colorectal Cancer Drugs Market, 2015-2025
3.1 Global Colorectal Cancer Drugs Market Forecast 2015-2025
3.2 Geographical Colorectal Cancer Drugs Market Forecasts 2015-2025
3.2.1 The US Colorectal Cancer Drugs Market, 2015-2025
3.2.1.1 The US Colorectal Cancer Drugs Market Forecast – Stagnant Growth
3.2.2 The Japanese Colorectal Cancer Drugs Market, 2015-2025
3.2.2.1 The Japanese Colorectal Cancer Drugs Market Forecast – High Price of Biosimilars Will Drive the Market
3.2.3 The EU Colorectal Cancer Drugs Market, 2015-2025
3.2.3.1 The EU Colorectal Cancer Drugs Market Forecast – Tough Regulatory Environment Will Slow Market Growth
3.2.4 The APAC Countries Colorectal Cancer Drugs Market, 2015-2025
3.2.4.1 The APAC Colorectal Cancer Drugs Market Forecast – Market Will Be Stimulated by Rising Incidence of Cancer Owing to Changes of Lifestyle
3.2.5 Rest of the World Colorectal Cancer Drugs Market, 2015-2025
3.2.5.1 Rest of the World Colorectal Cancer Drugs Market Forecast

4. The Top Colorectal Cancer Drugs: Revenue Forecasts, 2015-2025
4.1 Avastin (Roche)
4.1.1 Avastin Revenue Forecast – Leader of the Pack
4.1.2 Roche
4.2 Erbitux (BMS/Merck KGaA)
4.2.1 Erbitux Revenue Forecast – Will its Revenue be Eroded by Biosimilars?
4.2.2 BMS
4.2.3 Merck KGaA
4.3 Xeloda (Roche)
4.3.1 Xeloda Revenue Forecast – Declining Sharply
4.4 Vectibix (Amgen)
4.4.1 Vectibix Revenue Forecast – Sales Will Grow During the First Half of the Forecast Period
4.4.2 Amgen
4.5 Eloxatin (Sanofi)
4.5.1 Eloxatin Revenue Forecast – Declining Slowly
4.5.2 Sanofi
4.6 Zaltrap (Sanofi/Co-developed with Regeneron)
4.6.1 Zaltrap Revenue Forecast – Sales Expected to Grow Significantly Until 2020
4.7 Stivarga (Bayer)
4.7.1 Stivarga Revenue Forecast – Positive Growth Trend
4.7.2 Bayer
4.8 TS-1 (Taiho Pharmaceuticals)
4.8.1 TS-1 Revenue Forecast
4.8.2 Taiho Pharmaceuticals
4.9 Cyramza (Eli Lilly)
4.9.1 Cyramza Revenue Forecast – Additional Approval for mCRC Will Drive Sales
4.9.2 Eli Lilly

5. Emerging Therapies
5.1 Lonsurf (Taiho Pharmaceuticals) – Approved in Japan
5.2 Sym-004 (Symphogen) – Promising Results in Early Human Clinical Trials
5.3 IMMU-130/Labetuzumab-SN-38 (Immunomedics) – ADC with High Anti-Tumour Activity

6. R&D Pipelines for Colorectal Cancer Treatment
6.1 CPX-1 (Celator Pharmaceuticals) – Combination of Irinotecan HCl and Floxuridine
6.2 CT-011/Pidilizumab (CureTech) – Binds to PD-1
6.3 Dabrafenib/Tafinlar (GSK) – Inhibitor of B-Raf
6.4 E7820 (Eisai) – Inhibits Integrin Alpha 2
6.5 Entinostat (Syndax Pharmaceuticals) – Exhibits a Wide Range of Anti-Tumour Activity
6.6 Ganetespib (Synta Pharmaceuticals) – Inhibits Hsp90
6.7 LGX818/Encorafenib (Novartis) – Investigated in Several Trials
6.8 ABT-869/Linifanib (Abbott Laboratories) – Inhibits VEGF and PDGF Receptors
6.9 MORAb-004/Ontuxizumab (Morphotek, Inc.) – Targets Endosialin
6.10 Onartuzumab (Genentech) – Targets the Protein MET
6.11 JX-594 (SillaJen) – Oncolytic Virus
6.12 PF-05212384 (Pfizer) – PI3K/mTOR Inhibitor
6.13 Simtuzumab (Gilead) – Highly Selective for LOXL2
6.14 Talaporfin Sodium (Aptocine, Light Sciences Oncology) – Water-Soluble Drug
6.15 Tivantinib (ARQ 197; ArQule, Daiichi Sankyo) – An Option for EGFR-resistant MET-High mCRC Patients
6.16 Tivozanib (Astellas Pharma/Aveo Pharmaceuticals) – Inhibits VEGF Receptors
6.17 Trametinib (Mekinist, GlaxoSmithKline) – Blocks MEK1 and MEK2
6.18 Veliparib (ABT-888, AbbVie) – An Oral PARP
6.19 RG7221/ RO5520985/Vanucizumab (Roche) – Binds Ang2 and VEGF-A
6.20BKM-120/Buparlisib (Novartis) – Reduces Cellular Levels of Phosphorylated AKT
6.21 BYL-719/Alpelisib (Novartis)

7. Qualitative Analysis of the Colorectal-Cancer Drugs Market 2015-2025
7.1 SWOT Analysis of the Colorectal Cancer Drugs Market
7.1.1 Strengths
7.1.1.1 Rising Incidence of Cancer – Ageing Population
7.1.1.2 Multiple Treatment Options Are Usually Needed
7.1.2 Weaknesses
7.1.2.1 The Challenges of Drug Development
7.1.2.2 The Complex Nature of Cancer
7.1.3 Opportunities in the Cancer Drugs Market
7.1.3.1 The Advancement of Research
7.1.3.2 A Shift Towards Personalisation
7.1.4 Threats Facing the Cancer Drugs Market
7.1.4.1 The Threat of Regulation
7.2.1 Social Factors: The Cost of Living Longer
7.2.2 Technological Developments: Making the Market Move Forward
7.2.3 Economic Pressure: Treatment’s Hefty Price Tag
7.2.4 Political Issues: Governmental Involvement in Treatment

8. Research Interviews from Our Survey – 2015
8.1 Dr. Philip M. Arlen, President and CEO, Precision Biologics, Inc., US
8.1.1 Less Than 1% of Colonoscopies Screening Reveal Cancer
8.1.2 Market Driver – New Drugs with Novel MoA and Favourable Safety Profile
8.1.3 Ensituximab – Developed From a Tumour-Derived Cancer Vaccine
8.1.4 60% of Patients with Colorectal and Pancreatic Cancer Express the Ensituximab Target
8.2 Dr. John Beadle, CEO of PsiOxus Therapeutics, UK
8.2.1 Significant Unmet Need – Effective Treatments for MSI Normal and MSI Low Patients
8.2.2 Checkpoint Inhibitors – Work Well in MSI High Patients
8.2.3 Enadenotucirev Remains Stable in Human Blood
8.2.4 Enadenotucirev – Positioning in the Colorectal Cancer Market?

9. Conclusions of the Study
9.1 Patent Expiries and the Impact of Biosimilars
9.2 The US – Still the Largest National Market
9.3 APAC – Will Show the Fastest Growth
9.4 Colorectal Cancer Drugs R&D Pipeline – Crowded, but How Many Promising Drugs?
9.5 Concluding Remarks


【レポート販売概要】

■ タイトル:大腸癌治療薬の世界市場:治療、研究開発、市場予測
■ 英文:Colorectal Cancer Drugs Industry and Market: Therapies, R&D and Forecasts 2015-2025
■ 発行日:2015年11月
■ 調査会社:visiongain
■ 商品コード:VGAIN5112513
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。